title: Liraglutide as a potentially useful agent for regulating appetite in diabetic patients with hypothalamic hyperphagia and obesity.
abstract: Hypothalamic hyperphagia and obesity are characterized by a lack of satiety and an abnormally high appetite that is difficult to control. We herein report the cases of two patients with hypothalamic hyperphagia and obesity with MRI-detectable hypothalamic lesions. These patients suffered from diabetes mellitus associated with an abnormal eating behavior and weight gain. Liraglutide was successfully used to treat their diabetes mellitus and suppress their abnormal appetites. Glucagon-like peptide-1 analogues, including liraglutide, are promising treatment options in patients with hypothalamic hyperphagia and obesity, as these agents enhance the hypothalamic input of the satiety signal, which is lacking in such patients.
authors.affiliation: Department of Endocrinology and Metabolism, Nagasaki University Graduate School of Biomedical Sciences, Japan.
authors.forename: Takao
authors.initials: T
authors.lastname: Ando
authors.forename: Ai
authors.initials: A
authors.lastname: Haraguchi
authors.forename: Tomoe
authors.initials: T
authors.lastname: Matsunaga
authors.forename: Shoko
authors.initials: S
authors.lastname: Natsuda
authors.forename: Hironori
authors.initials: H
authors.lastname: Yamasaki
authors.forename: Toshiro
authors.initials: T
authors.lastname: Usa
authors.forename: Atsushi
authors.initials: A
authors.lastname: Kawakami
mesh_terms: D000328:Adult; D000368:Aged; D001066:Appetite / Q000187:drug effects*; D003924:Diabetes Mellitus, Type 2 / Q000150:complications*; D052216:Glucagon-Like Peptide 1 / Q000008:administration & dosage / Q000031:analogs & derivatives*; D006801:Humans; D006963:Hyperphagia / Q000150:complications / Q000188:drug therapy*; D007004:Hypoglycemic Agents / Q000008:administration & dosage; D007027:Hypothalamic Diseases / Q000150:complications / Q000188:drug therapy*; D007030:Hypothalamo-Hypophyseal System / Q000187:drug effects; D000069450:Liraglutide; D008297:Male; D009765:Obesity / Q000150:complications* / Q000517:prevention & control*; D016896:Treatment Outcome
chemical_list: D007004:Hypoglycemic Agents; D000069450:Liraglutide; D052216:Glucagon-Like Peptide 1